The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
Manasvi Gupta,1 Shiavax Rao,2 Gaurav Manek,1 Gregg C Fonarow,3 Raktim K Ghosh4 1Department of Internal Medicine, University of Connecticut, Hartford, CT, USA; 2Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA; 3Department of Medicine, Ronald Reagan UCLA Medical Center, Los...
Main Authors: | Gupta M, Rao S, Manek G, Fonarow GC, Ghosh RK |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-08-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/the-role-of-dapagliflozin-in-the-management-of-heart-failure-an-update-peer-reviewed-fulltext-article-TCRM |
Similar Items
-
DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
by: Edgardo Kaplinsky
Published: (2020-02-01) -
Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01) -
Costs and healthcare utilisation of patients with heart failure in Spain
by: Carlos Escobar, et al.
Published: (2020-10-01) -
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study
by: Mikhail M. Batyushin
Published: (2021-06-01) -
Report from the 5th cardiovascular outcome trial (CVOT) summit
by: Oliver Schnell, et al.
Published: (2020-04-01)